Company Focus
Novartis
Latest Novartis News
Biotechnology
Rare disease drug pricing has long rested on a simple trade-off. Small patient populations and high development costs justified higher prices, and payers largely accepted that logic because the overall budget impact remained limited. That balance is becoming harder to maintain as orphan drugs now account for a growing share of new launches and an increasing portion of drug spending. 8 April 2026
Related News
Insights
Company Spotlight
A biotechnology company, based in China, developing car-t-based therapeutics for haematological and metabolic and endocrine diseases with a focus on addressing unmet medical need.
Latest News & Features of interest to Novartis
Biotechnology
Danish biotech Adcendo today announced the successful closing of an oversubscribed $75 million Series C financing round. 14 April 2026
Biotechnology
Anglo-Irish biopharma SynOx Therapeutics announced that the US Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to emactuzumab for the treatment of tenosynovial giant cell tumors (TGCT) patients that are not amenable to or who would not benefit from surgery. 14 April 2026
Pharmaceutical
Novo Nordisk has announced a strategic partnership with OpenAI, the US AI research and deployment company. 14 April 2026
Generics
The Russian drugmaker Binnopharm Group, which was founded by the local billionaire Vladimir Yevtushenkov, hopes to acquire Akrikhin, the local drugmaker, which is owned by the Polish-Dutch company Polpharma and which produces some important and best selling drugs in the Russian market. 14 April 2026
Biotechnology
Dutch biotech Laigo Bio, which is pioneering novel and highly differentiated therapies using its proprietary SureTACs precision membrane protein degradation platform, has appointed Dr Richard Sainson as its new chief scientific officer (CSO). 14 April 2026
Biotechnology
US biotech major Regeneron Pharmaceuticals and Australian radiopharmaceuticals specialist Telix Pharmaceuticals have announced a collaboration, sending the latter company’s shares up by 8% in Monday’s trading. 13 April 2026
Pharmaceutical
Revolution Medicines today announced positive top-line results from its global, randomized, controlled Phase III RASolute 302 clinical trial evaluating daraxonrasib in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who had been previously treated. 13 April 2026
Generics
The Russian Ministry of Health has begun more active cancelling of tenders for drug procurements, waiting for the launch of cheaper generics, as the federal budget experiences a shortage of funds for procurements of expensive original drugs. 13 April 2026
Pharmaceutical
Lotte Bjerre Knudsen, chief scientific advisor to the chief scientific officer, vice president of innovation and data experimentation advancement (IDEA) at Danish pharma major Novo Nordisk, is to leave the company after 36 years. 13 April 2026
Biotechnology
UK pharma major GSK has announced positive findings from its global Phase I BEHOLD-1 clinical trial for mocertatug rezetecan (or Mo-Rez for short), a novel antibody-drug conjugate (ADC) targeting the B7-H4 antigen. 13 April 2026
Latest In Brief for Novartis
Pharmaceutical
Israel-based generics giant Teva Pharmaceutical Industries and France’s Medincell announced that the US Food and Drug Administration has accepted the New Drug Application for olanzapine extended-release injectable suspension (TEV-'749) for the treatment of schizophrenia in adults. 21 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze